CD44 and neoplasm: A phase II clinical trial of patients with gastric cancer showed that patients who received chemotherapy with Vismodegib–a hedgehog inhibitor–held a survival advantage if their tumour had high expression of CSC marker CD44 (Yoon et al., 2014).